# Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

* Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval
* Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution
* Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management
* NTRB boosting their profile and credibility with its recent membership to the Russel Indexes

 The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity with public safety, innovative technologies are emerging that could reshape how these powerful drugs are administered.

 Nutriband and Kindeva Reach Key Manufacturing Milestone

 One company aiming to bridge this gap is Nutriband (NASDAQ: NTRB). Recently, Nutriband announced it has completed commercial manufacturing process scale-up for its lead product, AVERSA(TM) Fentanyl, in partnership with global contract manufacturer Kindeva Drug Delivery. The achievement represents a…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/nutriband-inc-nasdaq-ntrb-added-to-four-key-indexes-rethinking-opioid-safety-in-a-time-of-crisis/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-and-kindeva-achieve-key-milestone-in-opioid-safety-innovation/045d2c26c60dd126a4b1421f17afd865) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1lqsw09/nutriband_and_kindeva_achieve_key_milestone_in/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/3/roamHXwj.webp)